In markets generally dominated by just a few major players, it can be tempting to focus solely on the most visible names. Yet, the true value of active management often lies beyond the indices—where the less obvious opportunities can be found.
To uncover these off-the-beaten path ideas, Kristofer Barrett, Fund Manager of Carmignac Investissement, supported by a team of analysts, explores major structural trends and promising market segments by mapping an entire value chain within specific sectors to understand its deeper dynamics and its biggest players: who creates value, who captures it, which players hold genuine pricing power, and how relationships between clients, suppliers, and competitors shape sector profitability. On this basis, the fund manager selects innovative, often niche companies whose current valuations fail to reflect the strength of their fundamentals or their growth potential. Some of these firms may be absent from traditional indices and portfolios, yet play a vital role in keeping ecosystems running smoothly.
Investing across different levels of the same ecosystem helps diversify performance drivers. Behind every global leader stands a network of actors—suppliers, service providers, and niche specialists—whose often understated contribution is essential to the sector’s overall momentum. Today, several value chains coexist within the fund. Alongside a range of technology sub-segments, the portfolio also includes sectors such as aerospace, automotive, and financial infrastructure. Two areas illustrate this approach particularly well: artificial intelligence (AI) data centers and healthcare companies that are relatively immune to fluctuations in drug prices.
Anatomy of an ai data center: mapping the value chain
In the United States, the energy capacity of data centers is expected to quintuple by 2030, reflecting the surging demand for computing power1. This rapid expansion of AI is intensifying pressure on hyperscale data centers, driving substantial infrastructure investments to scale their computing and storage capabilities. While companies such as Nvidia and TSMC are often cited as the cornerstones of this relentless race for computing power, many lesser-known—but equally essential—players are also benefiting from this momentum.
When building a data center, semiconductors account for roughly 50% of capital expenditure, while the remaining 50% is devoted to costs related to storage, energy, and cooling1.
As Jensen Huang, CEO of Nvidia, aptly noted: “electricians and plumbers will be needed by the hundreds of thousands in the new working world thanks to an accelerating boom in data centers.”2
Regardless of the value chain, our investment criteria remain unchanged: profitable growth, solid financial structures often backed by a positive net cash position, and attractive valuations.
A few examples of investments include3:
- Comfort Systems (not part of the reference indicator4) – A company specializing in mechanical, electrical, plumbing, and control systems for buildings. It directly benefits from the rapid expansion in data center construction.
- Asia Vital Components (0.01% of the reference indicator) – A Taiwan-based company focused on thermal management solutions, notably liquid cooling systems, which are essential for high-density AI servers.
- Celestica (0.03% of the reference indicator) – Designs and delivers custom hardware platforms—including compute nodes, storage systems, switches, and cooling solutions—that enable AI data centers to operate with high throughput and low latency.
Healthcare: spotting the value chain players shielded from political uncertainty
The Healthcare sector has been the laggard of the equity markets over the past few years. Policy noise in the US regarding tariffs has been a major headwind recently, but even before that investors’ focus were drawn elsewhere as areas such as technology raced ahead. We see three key current threats to the healthcare sector: efforts to control drug pricing, tariffs, and possible tax changes. There is little doubt the sector is trading cheaply. The question is where to find good value considering the risks. Investing in healthcare goes far beyond large pharmaceutical companies, which are often in the spotlight of legislative scrutiny. Within this broad ecosystem—where every component of the value chain, from laboratories to distributors and from medical equipment manufacturers to technology service providers, play a decisive role—there are companies that remain largely insulated from the pressures affecting the wider sector.
A few examples of investments include:
- Doximity (not part of the reference indicator) – The leading digital platform dedicated to healthcare professionals in the United States, bringing together over 80% of the country’s doctors. As a true digital infrastructure for the medical sector, it facilitates communication, telemedicine, and the sharing of clinical information. Its business model enables it to deliver profit margins above 40% by 20255.
- Cencora (0.03% of the reference indicator) – One of the largest pharmaceutical distributors in North America, serving both retail pharmacies and hospitals. This defensive company, operating in an inherently defensive sector, derives its growth from the volume of drugs distributed in the United States. The company delivers high returns, with low but stable margins.
Putting ‘off the beaten track’ into action
In Carmignac Investissement, we fully embrace an active and differentiated management approach. We invest in companies that we believe offer sustainable growth potential, strategic positions within their value chains, and attractive valuations.
Here’s how this approach is reflected in our portfolio construction as at the end of October 2025:
- Nearly a quarter of our holdings — 20 companies in total — are not included in the MSCI ACWI index.
- Our active share stands at 79%, underscoring our determination to go beyond market consensus.
When our convictions are strong, we are not afraid to express them through meaningful positions:
- TSMC (9.6%6 vs. 1.2% in the reference indicator) – a key player in advanced semiconductors;
- SK Hynix (3.0% vs. 0.1%) – South Korea’s leading memory chip manufacturer;
- Cencora (2.6% vs. 0.1%) – a US leader in pharmaceutical distribution.
These allocations reflect our philosophy: daring to step off the beaten path to capture growth where it is truly being built.
1Carmignac, 30/10/2025.
2The Free Press Journal: https://www.freepressjournal.in/tech/nvidia-ceo-jensen-huang-warns-gen-z-skip-coding-ai-will-drive-huge-demand-for-plumbers-electricians-carpenters. 03/10/2025.
3Reference to certain securities and financial instruments is for illustrative purposes to. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. Portfolio allocations may change at any time without notice.
4MSCI AC World Index.
5Sources: Bloomberg, profit Margin Est 2025.
6Positions data valid as at 31st October 2025. Portfolio is subject to change without notice.
I. Off the beaten path approach of Carmignac Investissement
Carmignac Investissement A EUR Acc
- Recommended minimum investment horizon
- 5 years
- Risk indicator*
- 4/7
- SFDR - Fund Classification**
- Article 8
*Risk Scale from the KID (Key Information Document). Risk 1 does not mean a risk-free investment. This indicator may change over time. **The Sustainable Finance Disclosure Regulation (SFDR) 2019/2088 is a European regulation that requires asset managers to classify their funds as either 'Article 8' funds, which promote environmental and social characteristics, 'Article 9' funds, which make sustainable investments with measurable objectives, or 'Article 6' funds, which do not necessarily have a sustainability objective. For more information please refer to https://eur-lex.europa.eu/eli/reg/2019/2088/oj.
Main risks of the fund
Fees
- Entry costs
- 4.00% of the amount you pay in when entering this investment. This is the most you will be charged. Carmignac Gestion doesn't charge any entry fee. The person selling you the product will inform you of the actual charge.
- Exit costs
- We do not charge an exit fee for this product.
- Management fees and other administrative or operating costs
- 1.50% of the value of your investment per year. This estimate is based on actual costs over the past year.
- Performance fees
- 20.00% max. of the outperformance once performance since the start of the year exceeds that of the reference indicator and if no past underperformance still needs to be offset. The actual amount will vary depending on how well your investment performs. The aggregated cost estimation above includes the average over the last 5 years, or since the product creation if it is less than 5 years.
- Transaction Cost
- 1.30% of the value of your investment per year. This is an estimate of the costs incurred when we buy and sell the investments underlying the product. The actual amount varies depending on the quantity we buy and sell.
Performance
| Carmignac Investissement | 2.1 | 4.8 | -14.2 | 24.7 | 33.7 | 4.0 | -18.3 | 18.9 | 25.0 | 18.6 |
| Reference Indicator | 11.1 | 8.9 | -4.8 | 28.9 | 6.7 | 27.5 | -13.0 | 18.1 | 25.3 | 8.6 |
| Carmignac Investissement | + 19.8 % | + 11.5 % | + 8.7 % |
| Reference Indicator | + 15.5 % | + 14.8 % | + 10.8 % |
Source: Carmignac at 31 Oct 2025.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor).
Reference Indicator: MSCI AC World NR index
Articles that may interest you
A decade since Paris, can COP30 deliver another defining moment?
Quarter 3 2025: Our active stewardship illustrated
Carmignac appoints business development manager for Switzerland
Marketing communication. Please refer to the KID/KIID, prospectus of the fund before making any final investment decisions.
This material may not be reproduced, in whole or in part, without prior authorisation from the Management Company. This material does not constitute a subscription offer, nor does it constitute investment advice. This material is not intended to provide, and should not be relied on for, accounting, legal or tax advice. This material has been provided to you for informational purposes only and may not be relied upon by you in evaluating the merits of investing in any securities or interests referred to herein or for any other purposes. The information contained in this material may be partial information and may be modified without prior notice. They are expressed as of the date of writing and are derived from proprietary and non-proprietary sources deemed by Carmignac to be reliable, are not necessarily all-inclusive and are not guaranteed as to accuracy. As such, no warranty of accuracy or reliability is given and no responsibility arising in any other way for errors and omissions (including responsibility to any person by reason of negligence) is accepted by Carmignac, its officers, employees or agents.
Past performance is not necessarily indicative of future performance. Performances are net of fees (excluding possible entrance fees charged by the distributor). The return may increase or decrease as a result of currency fluctuations, for the shares which are not currency-hedged.
Reference to certain securities and financial instruments is for illustrative purposes to highlight stocks that are or have been included in the portfolios of funds in the Carmignac range. This is not intended to promote direct investment in those instruments, nor does it constitute investment advice. The Management Company is not subject to prohibition on trading in these instruments prior to issuing any communication. The portfolios of Carmignac funds may change without previous notice. The reference to a ranking or prize, is no guarantee of the future results of the UCIS or the manager.
Morningstar Rating™ : © Morningstar, Inc. All Rights Reserved. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
Access to the Funds may be subject to restrictions regarding certain persons or countries. This material is not directed to any person in any jurisdiction where (by reason of that person’s nationality, residence or otherwise) the material or availability of this material is prohibited. Persons in respect of whom such prohibitions apply must not access this material. Taxation depends on the situation of the individual. The Funds are not registered for retail distribution in Asia, in Japan, in North America, nor are they registered in South America. Carmignac Funds are registered in Singapore as restricted foreign scheme (for professional clients only). The Funds have not been registered under the US Securities Act of 1933. The Funds may not be offered or sold, directly or indirectly, for the benefit or on behalf of a «U.S. person», according to the definition of the US Regulation S and FATCA.
The risks, fees and ongoing charges are described in the KID (Key Information Document). The KID must be made available to the subscriber prior to subscription. The subscriber must read the KID. Investors may lose some or all their capital, as the capital in the funds are not guaranteed. The Funds present a risk of loss of capital.
The Funds’ prospectus, KIDs, NAVs and annual reports are available at www.carmignac.com/en, or upon request to the Management Carmignac Portfolio refers to the sub-funds of Carmignac Portfolio SICAV, an investment company under Luxembourg law, conforming to the UCITS Directive. The French investment funds (fonds communs de placement or FCP) are common funds in contractual form conforming to the UCITS or AIFM Directive under French law.
In the United Kingdom: the Funds’ respective prospectuses, KIIDs and annual reports are available at www.carmignac.com/en-gb, or upon request to the Management Company, or for the French Funds, at the offices of the acilities Agent, Carmignac UK Ltd, 2 Carlton House Terrace, London, SW1Y 5AF. This document was prepared by Carmignac Gestion, Carmignac Gestion Luxembourg or Carmignac UK Ltd. FP Carmignac ICVC (the “Company”) is an Investment Company with variable capital incorporated in England and Wales under registered number 839620 and is authorised by the FCA with effect from 4 April 2019 and launched on 15 May 2019. FundRock Partners Limited is the Authorised Corporate Director (the “ACD”) of the Company and is authorised and regulated by the FCA. Registered Office: Hamilton Centre, Rodney Way, Chelmsford, Essex, CM1 3BY, UK; Registered in England and Wales with number 4162989. Carmignac Gestion Luxembourg SA has been appointed as the Investment Manager and distributor in respect of the Company. Carmignac UK Ltd (Registered in England and Wales with number 14162894) has been appointed as a sub-Investment Manager of the Company and is authorised and regulated by the Financial Conduct Authority with FRN:984288.
In Switzerland: the prospectus, KIDs and annual report are available at www.carmignac.com/en-ch, or through our representative in Switzerland, CACEIS (Switzerland), S.A., Route de Signy 35, CH-1260 Nyon. The paying agent is CACEIS Bank, Montrouge, Nyon Branch / Switzerland, Route de Signy 35, 1260 Nyon.
The Management Company can cease promotion in your country anytime. Investors have access to a summary of their rights in English on the following links: UK ; Switzerland ; France ; Luxembourg ; Sweden.
For Carmignac Portfolio Long-Short European Equities: Carmignac Gestion Luxembourg SA in its capacity as the Management Company for Carmignac Portfolio, has delegated the investment management of this Sub-Fund to White Creek Capital LLP (Registered in England and Wales with number OCC447169) from 2nd May 2024. White Creek Capital LLP is authorised and regulated by the Financial Conduct Authority with FRN : 998349.
Carmignac Private Evergreen refers to the Private Evergreen sub-fund of the SICAV Carmignac S.A. SICAV – PART II UCI, registered with the Luxembourg RCS under number B285278.